Biosimilars Market Research Reports & Industry Analysis
The worldwide prescription generic drug market has stood the test of time and has endured numerous growing pains. However, it has evolved into a formidable and important participant in the complex world of health care. Generic drugs continue to represent one of the greatest values in healthcare and are of great importance in the area of biopharmaceuticals as well because these products are among the most expensive treatments currently on the market.
Generic drug manufacturers are poised for strong growth in the future because the patent protection for a host of major biopharmaceuticals will expire and new legislative reforms in the generic drug approval process may facilitate bringing products to market. While there are many issues to address, the outlook for the promotion of biosimilars is favorable in the next five years.
Biosimilars Industry Research & Market Reports
-
Biosimilars Global Market Opportunities And Strategies To 2030: COVID-19 Growth And Change
... management with the critical information they need to assess the global biosimilars market as it emerges from the COVID 19 shut down. Reasons to Purchase Gain a truly global perspective with the most comprehensive report ... Read More
-
Global Regulatory Affairs Outsourcing Market Size study, by Services (Regulatory Consulting, Legal Representation, Regulatory Writing & Publishing, Product Registration & Clinical Trial Applications, Other Services) by Company Size (Small, Medium, Large) by Category (Drugs, Generics, Innovators, Biologics, Biotech, ATMPs, Biosimilars, Medical devices, Therapeutic, Diagnostic) by Indication (Oncology, Neurology, Cardiology, Immunology, Others) by Stage (Preclinical, Clinical, PMA (Post Market Authorization)) by End-use (Medical Device Companies, Pharmaceutical Companies, Biotechnology Companies) and Regional Forecasts 2022-2028
... Innovators, Biologics, Biotech, ATMPs, Biosimilars, Medical devices, Therapeutic, Diagnostic) by Indication (Oncology, Neurology, Cardiology, Immunology, Others) by Stage (Preclinical, Clinical, PMA (Post Market Authorization)) by End-use (Medical Device Companies, Pharmaceutical Companies, Biotechnology Companies) and Regional ... Read More
-
Biosimilars Market (Product: Recombinant Glycosylated Proteins, Recombinant Non-glycosylated Proteins, and Recombinant Peptides) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2022-2031
... market studies the past as well as the current growth trends and opportunities to gain valuable insights of the indicators of the market during the forecast period from 2022 to 2031. The report provides revenue ... Read More
-
Global Next-Generation Antibody Therapeutics Market: Market Segments: By Therapeutic Area (Oncology Autoimmune/Inflammatory); By Technology (Antibody-Drug Conjugates (ADCs), Bispecific Antibodies, Fc-engineered Antibodies, Antibody Fragments and Antibody-like Proteins & Biosimilar Antibody Products);and Region – Analysis of Market Size, Share & Trends for 2014 – 2019 and Forecasts to 2030
... Size, Share & Trends for 2014 – 2019 and Forecasts to 2030 Product Overview Use of a new improvised therapeutic antibody to form novel medicines for the treatment of different diseases includes next-generation antibody therapeutics. ... Read More
-
Global Oncology Biosimilars Market Size study, By Indication (Atopic Dermatitis, Postoperative Immunosuppression, Ulcerative Colitis, Psoriasis, Keratoconjunctivitis, Others), By Drug Class (Cyclosporine, Tacrolimus, Pimecrolimus, Others), By Route of Administration (Oral, Topical, Parenteral), By End-Users (Hospitals, Specialty Clinics, Homecare, Others), By Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Others), and Regional Forecasts 2022-2028
... Clinics, Homecare, Others), By Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Others), and Regional Forecasts 2022-2028 Global Oncology Biosimilars Market is valued approximately USD XX million in 2021 and is anticipated to grow with ... Read More
-
Herceptin Biosimilar Market, by Indication (Breast Cancer, Gastric Cancer, and Others), by Distribution Channel (Hospital, Oncology Centers, and Others) and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Size, Sh
... Share, Outlook, and Opportunity Analysis, 2022 - 2028 Trastuzumab, sold under the brand Herceptin, is a monoclonal antibody used for the treatment of breast cancer and gastric cancer. Herceptin is mainly used to treat patients ... Read More
-
MENA Biologics & Biosimilars Market, by Product Type (Influenza Vaccines, Factor VIII, (Xyntha, Octanate, Kovaltry, Advate, Koate, Adynovate, Kogenate, Hemlibra, Elocta, Recombinate, Feiba, Immunate, Alphanate and Novoeight), Erythropoietin (Epoetin Alfa
... and 4000IU) Darbepoietin Alfa (Aranesp) and Epoetin Alfa-epbx (Retacrit, Recormon)), Aflibercept (EYLEA), and Ziv-Aflibercept (ZALTRAP)), by Therapeutic Application (Hemophilia, Age-related Macular Degeneration, Kidney Diseases, Influenza, and Others), and by Region/Country (Gulf and Egypt) - Size, ... Read More
-
Cancer Supportive Care Products Market, By Drug Class (Nonsteroidal Anti- Inflammatory Drugs, Anti-Infective, Anti-Emetics, Monoclonal Antibodies, Erythropoietin Stimulating Agents, Opioid Analgesics, Bisphosphonates, Granulocyte Colony Stimulating Factor
... Cancer, Bladder Cancer, Leukemia, Ovary Cancer, Melanoma Cancer, Others), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Compounding Pharmacies), and By Region (North America, Latin America, Europe, Asia Pacific, Middle East & Africa) - Size, Share, ... Read More
-
High Potency APIs Market/HPAPI Market by Type (Innovative, Generic), Type of Synthesis (Synthetic, Biotech, Biosimilars, mAbs, Vaccines), Manufacturers (Captive, Merchant), Application (Oncology, Hormonal Imbalance, Glaucoma) Region - Global forecast to 2027
... projected to reach USD 39.6 Billion by 2027 from USD 24.5 billion in 2022, at a CAGR of 10.1% from 2022 to 2027. The market is driven by increasing demand for oncology drugs, growing demand ... Read More
-
Biosimilars Market - Global Industry Insights, Trends, Outlook, and Opportunity Analysis, 2022 - 2028
... identical copies of the original product and can be manufactured only when the patent for the original innovator product expires. Biosimilars are majorly used in therapeutic applications for the treatment of various types of cancer ... Read More
-
Biologics Market, by Drug Class (Monoclonal Antibody, Vaccine, Recombinant Insulin, Human Growth Hormone, Blood Factor, Fusion Protein, Erythropoietin, Recombinant Enzyme, Interferon, Colony-stimulating Factor, Cell Therapy, Gene Therapy, Oligonucleotides
... by Therapeutic Application (Oncology, Metabolic Disorders, Autoimmune/Immunologic Diseases, Ophthalmic Diseases, Inflammatory Bowel Diseases (IBDs), Respiratory Disorders, Neurological Disorders, Musculoskeletal Disorders (MSDs), Cardiovascular Diseases (CVDs), Infectious Diseases, and Others), by Distribution Channel (Hospitals Pharmacies, Retail Pharmacies, ... Read More
-
The 2023-2028 World Outlook for Biosimilars and Follow-on Biologics Drugs
... the latent demand, or potential industry earnings (P.I.E.), for the country in question (in millions of U.S. dollars), the percent share the country is of the region, and of the globe. These comparative benchmarks allow ... Read More
-
The 2023-2028 World Outlook for Erythropoietins
... for the country in question (in millions of U.S. dollars), the percent share the country is of the region, and of the globe. These comparative benchmarks allow the reader to quickly gauge a country vis-à-vis ... Read More
-
The 2023-2028 World Outlook for Erythropoietin Stimulating Agents
... potential industry earnings (P.I.E.), for the country in question (in millions of U.S. dollars), the percent share the country is of the region, and of the globe. These comparative benchmarks allow the reader to quickly ... Read More
-
The 2023-2028 World Outlook for Biobetters - High Efficiency and Economical Costs Foster Adoption
... For each year reported, estimates are given for the latent demand, or potential industry earnings (P.I.E.), for the country in question (in millions of U.S. dollars), the percent share the country is of the region, ... Read More
-
The 2023-2028 World Outlook for Generic Biosimilars
... earnings (P.I.E.), for the country in question (in millions of U.S. dollars), the percent share the country is of the region, and of the globe. These comparative benchmarks allow the reader to quickly gauge a ... Read More
-
The 2023-2028 World Outlook for Recombinant Non-Glycosylated Protein Biosimilars
... demand, or potential industry earnings (P.I.E.), for the country in question (in millions of U.S. dollars), the percent share the country is of the region, and of the globe. These comparative benchmarks allow the reader ... Read More
-
The 2023-2028 World Outlook for Generic Biosimilar Large Molecule Injectables
... the latent demand, or potential industry earnings (P.I.E.), for the country in question (in millions of U.S. dollars), the percent share the country is of the region, and of the globe. These comparative benchmarks allow ... Read More
-
The 2023-2028 World Outlook for Biosimilars and Related Biologics
... demand, or potential industry earnings (P.I.E.), for the country in question (in millions of U.S. dollars), the percent share the country is of the region, and of the globe. These comparative benchmarks allow the reader ... Read More
-
The 2023-2028 World Outlook for Biosimilars
... for the country in question (in millions of U.S. dollars), the percent share the country is of the region, and of the globe. These comparative benchmarks allow the reader to quickly gauge a country vis-à-vis ... Read More
-
The 2023-2028 World Outlook for Biosimilar Drugs
... earnings (P.I.E.), for the country in question (in millions of U.S. dollars), the percent share the country is of the region, and of the globe. These comparative benchmarks allow the reader to quickly gauge a ... Read More
-
The 2023-2028 World Outlook for Biosimilars and Follow-on Biologics
... demand, or potential industry earnings (P.I.E.), for the country in question (in millions of U.S. dollars), the percent share the country is of the region, and of the globe. These comparative benchmarks allow the reader ... Read More
-
The 2023-2028 World Outlook for Biosimilar Monoclonal Antibodies (mAb)
... demand, or potential industry earnings (P.I.E.), for the country in question (in millions of U.S. dollars), the percent share the country is of the region, and of the globe. These comparative benchmarks allow the reader ... Read More
-
The 2023-2028 World Outlook for Biosimilar Monoclonal Antibodies
... potential industry earnings (P.I.E.), for the country in question (in millions of U.S. dollars), the percent share the country is of the region, and of the globe. These comparative benchmarks allow the reader to quickly ... Read More
-
The 2023-2028 World Outlook for Erythropoietin Drugs
... earnings (P.I.E.), for the country in question (in millions of U.S. dollars), the percent share the country is of the region, and of the globe. These comparative benchmarks allow the reader to quickly gauge a ... Read More
Research Assistance
